Genomic aberrations and survival in chronic lymphocytic leukemia.
By Tephan, Tilgenbauer, Lexander, Röber, Onstanze, Öhner, Artin, Entz, Eter, Ichter. New England Journal of Medicine, 2000
3,254 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/b3c394ab35c33f77dbd0e02f9f152bf10fce96db
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Rheumatology
Citations in the corpus
- The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. (2010, background): “Deletion of 13q14 is mostly monoallelic (76% of cases), but can be biallelic (24%) (Döhner et al., 2000).”
- Evolution and impact of subclonal mutations in chronic lymphocytic leukemia (2013, positive): “We identified driver mutations that were consistently clonal (del(13q), MYD88, and trisomy 12 (Figure 3A), which appear to be relatively specific drivers of CLL or B cell malignancies (Beroukhim et al., 2010; Döhner et al., 2000; Ngo et al., 2010).”
- MicroRNAs in development and disease. (2011, background): “The chromosomal region 13q14 is frequently deleted in CLL patients and was, thus, predicted to harbor a tumor suppressor gene (146).”
- A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes (2006, background): “B cell chronic lymphocytic leukemia (CLL), the most common adult leukemia in the western world, is highly associated with loss of chromosomal region 13q14 (reviewed by Dohner et al. (2000)).”
- ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. (2003, background): “11 Important prognostic information in CLL can also be derived from cytogenetic analysis.(6) Notably, deletions of 11q and 17p are associated with rapidly progressive disease and short survival while deletions of 13q and trisomy 12 are associated with good and intermediate prognosis, respectively.”
- In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. (2005, background): “Several cytogenetic abnormalities (in particular, deletions at 17p13 and 11q22–23) are associated with unfavorable clinical courses, whereas a deletion at 13q14, in the absence of other abnormalities, bodes a slightly better clinical outcome (17).”
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). (2003, neutral): “Median age, y (range) 63 (36-79) 63 (36-86) Stage No.”
- microRNAs as oncogenes and tumor suppressors. (2007, background): “, 2002), the most common form of adult leukemia in the Western world (Dohner et al., 2000).”